Blood-borne angiotensin II (Ang II) has profound effects on the central nervous system, including regulation of vasopressin secretion and modulation of sympathetic outflow. However, the mechanism by which circulating Ang II affects the central nervous system remains largely unknown. We tested the hypothesis that increased circulating levels of Ang II activate angiotensin type I (AT 1 ) receptors in the subfornical organ (SFO), increasing the Ang II signalling in the rostral ventrolateral medulla (RVLM). Male Wistar rats were subcutaneously implanted with two 14-day osmotic minipumps filled with Ang II (150ng/kg/minute), Losartan (10mg/kg/day), or saline. In addition, AT 1 receptor mRNA levels in the SFO and RVLM were detected by reverse transcription polymerase chain reaction (RT-PCR). Infusion of Ang II-induced hypertension (134 ± 10 mmHg vs 98 ± 9 mmHg, n = 9, p < 0.05), which was blunted by concomitant infusion of Losartan (105 ± 8 vs 134 ± 10 mmHg, n = 9, p < 0.05). In addition, hexamethonium produced a greater decrease in blood pressure in Ang II-infused rats. Real time PCR revealed that chronic Ang II infusion induced an increase in AT 1 receptor mRNA levels in the RVLM and a decrease in the SFO. Taken together, using combined in vivo and molecular biology approaches, our data suggest that Ang II-induced hypertension is mediated by an increase in sympathetic nerve activity, which seems to involve up-regulation of AT 1 receptors in the RVLM and down-regulation of AT 1 receptors in the SFO.
Introduction
Ang II is the key peptide of the renin-angiotensin system. It is well established that blood-borne Ang II has profound effects on the central nervous system, including promotion of thirst, regulation of vasopressin secretion, and modulation of sympathetic outflow. In addition to the blood-borne Ang II, all components of the renin-angiotensin system are localized in the brain. 1 Within the brain, the renin-angiotensin system plays an important role in blood pressure regulation through its ability to modulate sympathetic nerve activity, especially in areas of the brain involved in the generation and modulation of the sympathetic discharge to the cardiovascular system. Among those, two major areas are responsible for the sympathoexcitatory actions of Ang II: the subfornical organ (SFO) and the rostral ventrolateral medulla (RVLM). 2, 3 The SFO is one of the circumventricular organs that lie outside the blood-brain barrier and thus have access to circulating and intraventricular Ang II. Moreover, the existence of angiotensinergic connections between the SFO and hypothalamic nuclei that control drinking and modulate sympathetic nerve activity has also been described. 4 In addition to the SFO, the RVLM contains bulbospinal neurons that mediate a number of sympathetically mediated reflexes and contribute to some disease states caused by sympathoexcitation such as hypertension. 5 Of note, a high density of AT 1 receptors is found in the RVLM, 6 and microinjection of Ang II into the RVLM produces an AT 1 receptormediated enhancement in sympathetic activity resulting in increases in blood pressure. 3, 7 Furthermore, the overexpression of AT 1 receptors in the RVLM increases blood pressure, 8 and the blockade of RVLM AT 1 receptors has been reported to reduce blood pressure in several forms of experimental hypertension. [9] [10] [11] Although various forms of hypertension are characterised by an elevation in Ang II levels in the periphery resulting in sympathetic overactivity, the signalling mechanism by which Ang II reaches the brain areas involved in blood pressure control in order to modulate the sympathetic nerve activity is largely unknown. In the present study we tested the hypothesis that increased circulating Ang II levels activate AT 1 receptors in the SFO, which in turn induce local production of Ang II within the brain, increasing the Ang II signalling in the RVLM via an overexpression of AT 1 receptors.
Material and methods

Animals
Adult male Wistar rats (250-280g), housed in a temperaturecontrolled room set to a 12:12 hour light-dark cycle with free access to standard rat chow (Labina®, Purina, Paulinea, SP, Brazil) were used. All procedures were approved by the Federal University of Paraiba Animal Care and Use Committee.
Experimental protocol
Rats were subcutaneously implanted with two 14-day osmotic minipumps (Alzet; Durect Corporation, Cupertino, CA, USA) filled with Ang II (150ng/kg/minute), Losartan (10mg/kg/day) or saline. The animals were divided into four experimental groups: (a) rats that were treated with saline + saline (saline group, n = 25); (b) rats that were treated with saline + Losartan (Losartan group, n = 27); (c) rats that were treated with Ang II + saline (Ang II group, n = 28); and (d) rats that were treated with Ang II + Losartan (Ang II + Losartan group, n = 28). After the drug infusion period, rats were anesthetised with ketamine and xylazine (75 and 10 mg/ kg, IP, respectively) and fitted with femoral venous and arterial catheters for drug injection and arterial pressure recordings, respectively as described by Braga. 7 Briefly, blood pressure measurements were performed ≥24 h after catheter implantation. On the day of the experiment, the mean arterial pressure (MAP) was recorded for one hour in conscious rats using the software DataTrax 2 (LabTrax 2-24T, World Precision Instruments, Sarasota, FL, USA). Following baseline blood pressure recordings, rats received a dose of hexamethonium (30 mg/kg, IV, Sigma-Aldrich, Saint Louis, MO, USA), a ganglionic blocker, in order to evaluate the contribution of the sympathetic activity to the hypertension.
RNA extraction and real-time quantitative RT-PCR analysis for AT 1 receptor in the SFO and the RVLM
In a subset of animals, rats were decapitated and brains flash frozen. Total RNA was extracted from fresh SFO and RVLM punches (5 rats per biological sample from each group, run in triplicate) using TRIzol Reagent® (Life Technologies, CA, USA) according to the manufacturer's protocols. The cDNA species were synthesised using SuperScript II (Life Technologies) from 1 µg of total RNA in a total volume of 20 µl with a random primer in accordance with the manufacturer's instructions. Real time PCR for AT 1 receptors and b-actin (internal control) was performed as follows: the total volume was 25 µl, which was comprised of 1X SYBR PCR master mix, 300 nM of forward primer (5′-TAA CAT GAG CTC AGC CGC CAA-3′), 300 nM of reverse primer (5′-TCG TGA GCC ATT TAG TCC GAT GCT-3′) and 25 ng of cDNA. The PCR reaction was carried out in triplicate using an ABI 7500 Fast Real-Time PCR System (Applied Biosystems) with the following thermal cycle parameters: 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 s each at 95°C and 1 min at 60°C. The data were analysed with Sequence Detection Software v1.4 (Applied Biosystems). The ΔCt relative expression approach (relative expression = 2 -ΔCt , where ΔCt = Ct target gene -Ct control gene ) was employed to examine mRNA expression of AT 1a receptors relative to b-actin.
Statistical Analysis
Results are expressed as mean ± SEM and were analysed by 'one-way' repeated measures analysis of variance (ANOVA) followed by a Tukey's post-test for multiple comparisons. All statistical analyses were performed using GraphPad Prism (v. 5.0 GraphPad Software, Inc). Statistical significance was defined as p < 0.05.
Results
Chronic angiotensin-II infusion induces sympatheticmediated hypertension
Rats treated with Ang II + saline presented a significant increase in blood pressure after 14 days of Ang II infusion compared to rats infused with saline + saline (134 ± 10 mmHg vs 98 ± 9 mmHg, n = 13, p < 0.05). On the other hand, rats treated with saline + Losartan did not become hypertensive when compared to saline + saline group (96 ± 7 mmHg vs 98 ± 9 mmHg, n = 12, p < 0.05). Furthermore, Ang II + Losartan treatment prevented hypertension (105 ± 8 mmHg vs 98 ± 9 mmHg, n = 13, p < 0.05). Data regarding blood pressure studies are illustrated in figure 1A .
To further investigate the contribution of the sympathetic nervous system to the hypertension elicited by Ang II, hexamethonium (30 mg/kg IV) was administered. This produced a greater fall in blood pressure in animals treated with Ang II + saline compared with animals treated with saline + saline, saline + Losartan and Ang II + Losartan (Ang II + saline: -78 ± 12 DmmHg, n = 13; saline + saline: -39 ± 6 DmmHg, n = 10; saline + Losartan: -42 ± 8 DmmHg, n = 12; Ang II + Losartan: -35 ± 15 DmmHg, n = 13), as shown in figure 1B .
Chronic Ang II infusion induces different AT 1 receptor expression in the SFO and in the RVLM
Changes in AT 1 receptor mRNA levels in the SFO and in the RVLM (the SFO being an important cardiovascular regulatory region that potentially influences Ang II signalling events at the RVLM) caused by two weeks of peripheral infusion of Ang II are presented in figure 2. As shown, AT 1 receptor mRNA levels in the RVLM were significantly increased by ~240% at day 14 of the Ang II + saline infusion compared with saline + saline control group (fold change = 3.40 ± 0.50, n = 15). In contrast, AT 1 receptor mRNA levels were significantly decreased in the SFO (fold change = 0.40 ± 0.20, n = 15) compared with saline + saline control. Of note, co-infusion with Losartan restored the AT 1 receptor mRNA levels to saline control in Ang II infused rats in both RVLM (fold change = 1.20 ± 0.50, n = 15) and SFO (fold change = 0.85 ± 0.0.35, n = 15).
Discussion
We report that chronic Ang II infusion evoked sympatheticmediated hypertension that was accompanied by an increase in AT 1 receptor mRNA levels in the RVLM, but decrease in the SFO, as determined by quantitative real-time RT-PCR. Collectively, the present studies implicate differential AT 1 receptor expression in the RVLM and SFO as a pivotal mechanism underlying the pressor and sympathoexcitatory effects evoked by increased circulating levels of Ang II.
The dose of Ang II employed in our study (administered subcutaneously via osmotic minipump) has been shown to increase plasma Ang II levels by approximately 2-fold and results in plasma concentrations within the pathophysiological range. 12, 13 The important role of the SFO, a circumventricular organ involved in integrating signals from circulating Ang II as well as local de novo production of this peptide, has been recognised. 2, 14 In the present investigation, we focused our attention on the RVLM because this brain region is the final relay point of the SFO-PVN-RVLM axis before transmission of signals generated by the brain renin-angiotensin system to the periphery. 15 Moreover, the RVLM controls sympathetic outflow and expresses renin and angiotensinogen locally. 5, 16 A recent, elegant study by Allen et al. 6 showed that targeting a constitutively active AT 1 receptor to glial cells in the RVLM caused hypertension. 8 In addition, studies have shown an overactive renin-angiotensin system and increased AT 1 receptors in the RVLM of spontaneously hypertensive rats. 10, 17 One mechanism by which Ang II raises blood pressure chronically is to increase sympathetic outflow, 18, 19 and here we demonstrate that the Ang II 'slow-pressor' model of hypertension involves increased sympathetic drive to the vasculature as suggested by the responses to hexamethonium, whereby the fall in blood pressure was significantly greater in the Ang II + saline infused rats. Interestingly, the increase in blood pressure was prevented by Losartan. The precise mechanism by which circulating Ang II activates the RVLM leading to increased sympathetic nerve activity and hypertension is largely unknown. However, is wellaccepted that all the components of the RAS are present in the central nervous system. 20 Therefore, it has been suggested that blood-borne Ang II increases sympathetic nerve activity primarily by binding to AT 1 receptors in the SFO. 21 Upon activation, neurons in the SFO excite neurons in the paraventricular nucleus of the hypothalamus (PVN). The importance of the SFO-PVN pathway has been demonstrated in a study in which in vitro patch clamp recordings of neurons in the SFO were retrograde labelled from the PVN, indicating that Ang II evokes inward currents, resulting in depolarization of neurons in the PVN. 22 Increasing evidence also suggests that neurons in the PVN activate AT 1 receptors in the RVLM. For example, in spontaneously hypertensive (but not normotensive) rats, injection of an AT 1 receptor antagonist into the RVLM or injection of muscimol into PVN both decrease mean arterial pressure, and one response occludes the other. 23 In addition, electrophysiological studies showed that Ang II excites neurons in the PVN that innervate the RVLM. Taken together these studies suggest that circulating Ang II activates the SFO-PVN-RVLM axis resulting in increased sympathetic nerve activity and hypertension. The mechanism underlying the activation of the SFO-PVN-RVLM axis remains unclear. It has been suggested that, upon AT 1 receptor activation, angiotensinergic neurons in the SFO would produce reactive oxygen species (ROS), which would activate the SFO-PVN pathway. Within the PVN, brain-borne Ang II would be formed and a second pool of ROS would be generated, activating RVLM-projecting glutamatergic and angiotensinergic neurons. Within the RVLM, glutamatergic and angiotensinergic neurons would modulate sympathetic outflow resulting in sympathetic overactivity and hypertension, where a third pool of ROS would also take place. 7, 24, 25, 26 Although an interesting possibility, this hypothesis awaits further investigation.
Chronic Ang II infusion resulted in an increase in AT 1 receptor mRNA levels in the RVLM as determined by quantitative real-time PCR, which indicates that enhanced Ang II signalling within the RVLM results in hypertension. Increasing the expression of the AT 1 receptors (up-regulation) in the RVLM would make the system more responsive to Ang II released from angiotensinergic neurons, therefore increasing the firing rate of sympathetic neurons within the RVLM. It is well established that the mitogen-activated protein kinase (MAPK) family members and c-Jun N-terminal kinases (JNK) are predominantly responsible for the induction of c-Fos and c-Jun, the two major components of AP-1. AP-1 DNA binding sites have been identified in the promoter region of the rat AT 1 R gene. 27 Therefore, it has been predicted that AP-1 is a key transcription factor involved in the Ang II-induced up-regulation of the AT 1 R in the central nervous system including the RVLM. 28 Interestingly, AT 1 receptor mRNA levels were decreased in the SFO of Ang-II infused rats. This phenomenon could be explained by the fact that increased circulating levels of Ang II would reduce the expression of AT 1 receptors (down-regulation) in that region, which is in intimate contact with the plasma Ang II. In fact, receptors are themselves subject to physiological regulation. When a high extracellular concentration of a messenger is maintained for some time, the total number of the target cell's receptors for that messenger may be down-regulated. Downregulation has the effect of desensitising the target cells, thus representing a local negative feedback mechanism. The main cause of down-regulation of plasma-membrane receptors is internalisation. More chronically, an actual decrease in the production of receptors may take place. Of note, growing evidence now suggests that hypertension and sympathoexcitation can be prevented/attenuated by selective genetic or pharmacological manipulation of AT 1 R mRNA expression specifically in the SFO or RVLM. In support of that concept, Zimmerman et al. 14 
have
shown that intracerebroventricular injection of losartan, an AT 1 receptor antagonist targeting the SFO, prevents the hypertension induced by chronic peripheral Ang II infusion in mice. In addition, we have shown that Ang II-induced hypertension is prevented by ablating the AT 1 receptors locally in the RVLM using the AT 1a flox transgenic mice and the adenovirus-mediated LoxP-Cre recombinase technique. 24 Taken together, these findings corroborate the importance of the AT 1 receptors in the SFO and in the RVLM for the development of Ang II-dependent hypertension.
One limitation of the present study is that we evaluate the AT 1 receptors mRNA expression at one time point (14 days of Ang II infusion). Measuring daily blood pressure, sympathetic nerve activity and the expression of AT 1 receptors in the RVLM and SFO would be ideal, since we could establish a time-course relationship among those parameters. However, this approach would be challenging and would require a huge number of animals, especially for the AT 1 receptor mRNA expression analysis, which is a terminal procedure. In support of our present data, we and others have experimental evidence documenting that, under continuous blood pressure recording by means of radiotelemetry, blood pressure starts rising by day 8-9 during Ang II infusion and remains elevated until the emptying of the infusion pump. 14, 24 We have also reported that at day 6 of Ang II infusion, the low frequency (LF) component of power spectral analysis from the systolic blood pressure, which is an index for sympathetic activity, is not altered compared to saline-infused animals. On the other hand, the LF component of the spectral analysis is increased by day 14 of Ang II infusion, suggesting that the sympathetic activity is increased at 2 weeks of Ang II infusion. 21 Looking at this previous experimental data, we might speculate that changes in AT 1 receptor expression in either the SFO or RVLM would only take place in the second week of Ang II infusion. This interesting possibility is certainly matter for future investigation.
Conclusions
Using combined in vivo and molecular biology approaches, we report that Ang II-induced hypertension is mediated by an increase in sympathetic nerve activity. The mechanism by which circulating Ang II causes sympathetic-mediated hypertension seems to involve up-regulation of AT 1 receptors in the RVLM and down-regulation of AT 1 receptors in the SFO.
